Centrexion Therapeutics Corporation
USPTO PatentsView assignee record - 36 granted patents across 6 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Centrexion ranks #8,759 of 49,997 tracked US assignees by granted-patent volume, with 36 patents across 6 technology areas.
- #8,759
- of 49,997 US assignees by volume
- Top 36%
- by Innovation Score (40.3/100)
- 25.2
- avg claims per patent
- +120%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R8759 · US Corporation #8,759 · 36 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL
- GRANTS-SMALL 36 grants
- UPPER-Q #8,759/49,997
- PHOTO-FINISH Celestica Technology…
- CPC-NARROW A61P · 6 areas
- INNOV-PAR 40.3/100
- CLAIMS-DENSE 25.2 claims/avg
- TYPE-USCORP US Corporation
- VEL-SURGE +120% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Celestica Technology Consultancy (Shanghai) Co. Ltd (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Centrexion’s 40.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Centrexion
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Fuso Pharmaceutical… · near
Fuso Pharmaceutical… · near
40 score
- Centrexion Therapeut… · this assignee
Centrexion Therapeut… · this assignee
40 score
- Resonance Companies · near
Resonance Companies · near
40 score
- Alto-Shaam · near
Alto-Shaam · near
40 score
- Intrexon Actobiotics · near
Intrexon Actobiotics · near
40 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Centrexion's Innovation Score is 40.3/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Centrexion?
Each dot is one of Centrexion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Centrexion’s own 25.2 claims/patent is ABOVE the 17.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Centrexion's grants concentrate
Centrexion Therapeutics Corporation is a focused PatentsView assignee: 6 CPC subclasses with 97.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (6 grants) versus a trough of 1 in 2018. By volume, Centrexion sits between Cosmogen SAS and Ciro Corporation.
Centrexion's three-year grant acceleration
Centrexion Therapeutics Corporation shows 10 grants in 2022–2024 against only 16 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Centrexion's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cosmogen SAS
Cosmogen SAS
36 patents
- Cradlepoint
Cradlepoint, Inc.
36 patents
- Cellink
CelLink Corporation
36 patents
- Celestica Technol…
Celestica Technology Consultancy (Shanghai) Co. Ltd
36 patents
- Ceterix Orthopaed…
Ceterix Orthopaedics, Inc.
36 patents
- Champion Power Eq…
Champion Power Equipment, Inc.
36 patents
- Circulite
CircuLite, Inc.
36 patents
- Ciro
Ciro Corporation
36 patents
- Centrexion Therap… ◀
Centrexion Therapeutics Corporation
36 patents
What this shows Centrexion holds 36 patents at rank #8,766, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Centrexion
By rank, the assignees closest to #8,766 in granted patent volume.
- Cosmogen SAS #8,762 · 36 patents
- Cradlepoint, Inc. #8,763 · 36 patents
- CelLink Corporation #8,764 · 36 patents
- Celestica Technology Consultancy (Shanghai) Co. Ltd #8,765 · 36 patents
- Ceterix Orthopaedics, Inc. #8,767 · 36 patents
- Champion Power Equipment, Inc. #8,768 · 36 patents
- CircuLite, Inc. #8,769 · 36 patents
- Ciro Corporation #8,770 · 36 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Centrexion's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Centrexion, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Centrexion ranks #541 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (40 here).
Centrexion's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
40 Top 36% higher than 64% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 5.6% |
| 2017 | 3 | 8.3% |
| 2018 | 1 | 2.8% |
| 2019 | 4 | 11.1% |
| 2020 | 6 | 16.7% |
| 2021 | 6 | 16.7% |
| 2022 | 4 | 11.1% |
| 2023 | 3 | 8.3% |
| 2024 | 3 | 8.3% |
| 2025partial year | 4 | 11.1% |
Which technologies does Centrexion Therapeutics Corporation patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Centrexion Therapeutics Corporation's patent record in context - here's where to go next.
- Centrexion Therapeutics Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 97.2% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #8,759 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Centrexion Therapeutics Corporation against Cosmogen SAS, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 40.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.